• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利:CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法,用中文像聊天一样搜索,搜遍4000万医学文献。AI智能推荐,让科研检索更轻松。

立即免费搜索

文件翻译

保留排版,准确专业,支持PDF/Word/PPT等文件格式,支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述,25分钟生成高质量综述,智能提取关键信息,辅助科研写作。

立即免费体验

与内皮功能障碍相关的重症 COVID-19 感染导致多器官功能障碍:治疗干预综述

Severe COVID-19 Infection Associated with Endothelial Dysfunction Induces Multiple Organ Dysfunction: A Review of Therapeutic Interventions.

作者信息

Matsuishi Yujiro, Mathis Bryan J, Shimojo Nobutake, Subrina Jesmin, Okubo Nobuko, Inoue Yoshiaki

机构信息

Department of Emergency and Critical Care Medicine, Faculty of Medicine, University of Tsukuba, Tsukuba 305-8575, Japan.

Pediatric Intensive Care Unit, University of Tsukuba Hospital, Tsukuba 305-8571, Japan.

出版信息

Biomedicines. 2021 Mar 10;9(3):279. doi: 10.3390/biomedicines9030279.

DOI:10.3390/biomedicines9030279
PMID:33801921
原文链接:https://pmc.ncbi.nlm.nih.gov/articles/PMC7999560/
Abstract

Since December 2019, the SARS-CoV-2 (COVID-19) pandemic has transfixed the medical world. COVID-19 symptoms vary from mild to severe and underlying chronic conditions such as pulmonary/cardiovascular disease and diabetes induce excessive inflammatory responses to COVID-19 and these underlying chronic diseases are mediated by endothelial dysfunction. Acute respiratory distress syndrome (ARDS) is the most common cause of death in COVID-19 patients, but coagulation induced by excessive inflammation, thrombosis, and disseminated intravascular coagulation (DIC) also induce death by multiple-organ dysfunction syndrome. These associations imply that maintaining endothelial integrity is crucial for favorable prognoses with COVID-19 and therapeutic intervention to support this may be beneficial. Here, we summarize the extent of heart injuries, ischemic stroke and hemorrhage, acute kidney injury, and liver injury caused by immune-mediated endothelial dysfunction that result in the phenomenon of multi-organ dysfunction seen in COVID-19 patients. Moreover, the potential therapeutic effect of angiotensin receptor blockers and angiotensin-converting enzyme inhibitors that improve endothelial dysfunction as well as the bradykinin storm are discussed.

摘要

自2019年12月以来,严重急性呼吸综合征冠状病毒2(SARS-CoV-2,即新冠病毒)大流行震惊了医学界。新冠病毒感染症状从轻微到严重不等,而诸如肺部/心血管疾病和糖尿病等潜在慢性疾病会引发对新冠病毒的过度炎症反应,且这些潜在慢性疾病是由内皮功能障碍介导的。急性呼吸窘迫综合征(ARDS)是新冠病毒感染患者最常见的死亡原因,但过度炎症引发的凝血、血栓形成和弥散性血管内凝血(DIC)也会因多器官功能障碍综合征导致死亡。这些关联表明,维持内皮完整性对于新冠病毒感染患者获得良好预后至关重要,支持这一点的治疗干预可能有益。在此,我们总结了免疫介导的内皮功能障碍所导致的心脏损伤、缺血性卒中和出血、急性肾损伤及肝损伤的程度,这些内皮功能障碍会导致新冠病毒感染患者出现多器官功能障碍现象。此外,还讨论了血管紧张素受体阻滞剂和血管紧张素转换酶抑制剂改善内皮功能障碍以及缓激肽风暴的潜在治疗效果。

https://cdn.ncbi.nlm.nih.gov/pmc/blobs/b229/7999560/a7c077e31d84/biomedicines-09-00279-g001.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/b229/7999560/a7c077e31d84/biomedicines-09-00279-g001.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/b229/7999560/a7c077e31d84/biomedicines-09-00279-g001.jpg

相似文献

1
Severe COVID-19 Infection Associated with Endothelial Dysfunction Induces Multiple Organ Dysfunction: A Review of Therapeutic Interventions.与内皮功能障碍相关的重症 COVID-19 感染导致多器官功能障碍:治疗干预综述
Biomedicines. 2021 Mar 10;9(3):279. doi: 10.3390/biomedicines9030279.
2
Recombinant ACE2 Expression Is Required for SARS-CoV-2 To Infect Primary Human Endothelial Cells and Induce Inflammatory and Procoagulative Responses.重组 ACE2 表达是 SARS-CoV-2 感染原代人血管内皮细胞并诱导炎症和促凝反应所必需的。
mBio. 2020 Dec 11;11(6):e03185-20. doi: 10.1128/mBio.03185-20.
3
A mechanistic model and therapeutic interventions for COVID-19 involving a RAS-mediated bradykinin storm.涉及 RAS 介导的缓激肽风暴的 COVID-19 的机械模型和治疗干预。
Elife. 2020 Jul 7;9:e59177. doi: 10.7554/eLife.59177.
4
Effects of SARS-CoV-2 on Cardiovascular System: The Dual Role of Angiotensin-Converting Enzyme 2 (ACE2) as the Virus Receptor and Homeostasis Regulator-Review.SARS-CoV-2 对心血管系统的影响:血管紧张素转换酶 2(ACE2)作为病毒受体和体内平衡调节剂的双重作用——综述。
Int J Mol Sci. 2021 Apr 26;22(9):4526. doi: 10.3390/ijms22094526.
5
Endothelial dysfunction in COVID-19: Current findings and therapeutic implications.COVID-19 中的血管内皮功能障碍:当前研究结果及治疗意义。
Atherosclerosis. 2020 Dec;314:58-62. doi: 10.1016/j.atherosclerosis.2020.10.014. Epub 2020 Oct 14.
6
COVID-19, Renin-Angiotensin System and Endothelial Dysfunction.新型冠状病毒肺炎、肾素-血管紧张素系统与血管内皮功能障碍。
Cells. 2020 Jul 9;9(7):1652. doi: 10.3390/cells9071652.
7
[ACE-inhibitors, angiotensin receptor blockers and severe acute respiratory syndrome caused by coronavirus].[血管紧张素转换酶抑制剂、血管紧张素受体阻滞剂与冠状病毒引起的严重急性呼吸综合征]
G Ital Cardiol (Rome). 2020 May;21(5):321-327. doi: 10.1714/3343.33127.
8
The Impact of COVID-19 On Comorbidities: A Review Of Recent Updates For Combating It.2019冠状病毒病对合并症的影响:抗击该病的最新进展综述
Saudi J Biol Sci. 2022 May;29(5):3586-3599. doi: 10.1016/j.sjbs.2022.02.006. Epub 2022 Feb 10.
9
Endothelial Dysfunction in COVID-19: Potential Mechanisms and Possible Therapeutic Options.新冠病毒病中的内皮功能障碍:潜在机制与可能的治疗选择
Life (Basel). 2022 Oct 14;12(10):1605. doi: 10.3390/life12101605.
10
The Contribution of Endothelial Dysfunction in Systemic Injury Subsequent to SARS-Cov-2 Infection.内皮功能障碍在 SARS-CoV-2 感染后继发全身损伤中的作用。
Int J Mol Sci. 2020 Dec 6;21(23):9309. doi: 10.3390/ijms21239309.

引用本文的文献

1
The silent legacy of COVID-19: exploring genomic instability in long-term COVID-19 survivors.新冠疫情的无声遗产:探索新冠长期幸存者的基因组不稳定性
BMC Infect Dis. 2025 Aug 19;25(1):1041. doi: 10.1186/s12879-025-11419-y.
2
Risk Factors for Pulmonary Embolism in Individuals Infected with SARS-CoV2-A Single-Centre Retrospective Study.感染SARS-CoV2个体发生肺栓塞的危险因素——一项单中心回顾性研究
Biomedicines. 2024 Apr 1;12(4):774. doi: 10.3390/biomedicines12040774.
3
Clinical assessment of endothelial function in convalescent COVID-19 patients: a meta-analysis with meta-regressions.

本文引用的文献

1
Preliminary evidence from a multicenter prospective observational study of the safety and efficacy of chloroquine for the treatment of COVID-19.一项关于氯喹治疗COVID-19安全性和有效性的多中心前瞻性观察性研究的初步证据。
Natl Sci Rev. 2020 May 28;7(9):1428-1436. doi: 10.1093/nsr/nwaa113. eCollection 2020 Sep.
2
Human kidney is a target for novel severe acute respiratory syndrome coronavirus 2 infection.人类肾脏是新型严重急性呼吸综合征冠状病毒 2 感染的靶器官。
Nat Commun. 2021 May 4;12(1):2506. doi: 10.1038/s41467-021-22781-1.
3
Vitamin D3 to Treat COVID-19: Different Disease, Same Answer.
恢复期 COVID-19 患者内皮功能的临床评估:荟萃分析与荟萃回归。
Ann Med. 2022 Dec;54(1):3234-3249. doi: 10.1080/07853890.2022.2136403.
4
Angiotensin II Exaggerates SARS-CoV-2 Specific T-Cell Response in Convalescent Individuals following COVID-19.血管紧张素 II 在 COVID-19 康复者中加剧了针对 SARS-CoV-2 的 T 细胞反应。
Int J Mol Sci. 2022 Aug 4;23(15):8669. doi: 10.3390/ijms23158669.
5
Simulation of COVID-19 symptoms in a genetically engineered mouse model: implications for the long haulers.在基因工程小鼠模型中模拟 COVID-19 症状:对长期患者的影响。
Mol Cell Biochem. 2023 Jan;478(1):103-119. doi: 10.1007/s11010-022-04487-0. Epub 2022 Jun 22.
6
Mechanism of Multi-Organ Injury in Experimental COVID-19 and Its Inhibition by a Small Molecule Peptide.实验性新型冠状病毒肺炎多器官损伤机制及其小分子肽抑制作用
Front Pharmacol. 2022 May 30;13:864798. doi: 10.3389/fphar.2022.864798. eCollection 2022.
7
Cardiopulmonary Exercise Performance and Endothelial Function in Convalescent COVID-19 Patients.康复期新冠患者的心肺运动表现与内皮功能
J Clin Med. 2022 Mar 7;11(5):1452. doi: 10.3390/jcm11051452.
8
A Review of the Potential Roles of Antioxidant and Anti-Inflammatory Pharmacological Approaches for the Management of Mild-to-Moderate Symptomatic COVID-19.抗氧化和抗炎药理学方法在管理轻至中度有症状 COVID-19 中的潜在作用综述。
Med Sci Monit. 2022 Mar 8;28:e936292. doi: 10.12659/MSM.936292.
9
Janus Kinase Signaling Pathway and Its Role in COVID-19 Inflammatory, Vascular, and Thrombotic Manifestations.Janus 激酶信号通路及其在 COVID-19 炎症、血管和血栓形成表现中的作用。
Cells. 2022 Jan 17;11(2):306. doi: 10.3390/cells11020306.
10
Single-Cell and Bulk RNASeq Profiling of COVID-19 Patients Reveal Immune and Inflammatory Mechanisms of Infection-Induced Organ Damage.单细胞和批量 RNA 测序分析 COVID-19 患者,揭示感染诱导的器官损伤的免疫和炎症机制。
Viruses. 2021 Dec 2;13(12):2418. doi: 10.3390/v13122418.
维生素D3治疗新冠肺炎:疾病不同,答案相同。
JAMA. 2021 Mar 16;325(11):1047-1048. doi: 10.1001/jama.2020.26850.
4
Effect of a Single High Dose of Vitamin D3 on Hospital Length of Stay in Patients With Moderate to Severe COVID-19: A Randomized Clinical Trial.一项随机临床试验:单次高剂量维生素 D3 对中重度 COVID-19 患者住院时间的影响。
JAMA. 2021 Mar 16;325(11):1053-1060. doi: 10.1001/jama.2020.26848.
5
Evaluation of the efficacy and safety of icatibant and C1 esterase/kallikrein inhibitor in severe COVID-19: study protocol for a three-armed randomized controlled trial.评估依卡替班特和 C1 酯酶/激肽释放酶抑制剂在重症 COVID-19 中的疗效和安全性:一项三臂随机对照试验研究方案。
Trials. 2021 Jan 20;22(1):71. doi: 10.1186/s13063-021-05027-9.
6
Hydroxychloroquine is associated with slower viral clearance in clinical COVID-19 patients with mild to moderate disease.在患有轻至中度疾病的临床新冠肺炎患者中,羟氯喹与病毒清除较慢有关。
Medicine (Baltimore). 2020 Dec 24;99(52):e23720. doi: 10.1097/MD.0000000000023720.
7
Von Willebrand factor propeptide in severe coronavirus disease 2019 (COVID-19): evidence of acute and sustained endothelial cell activation.严重 2019 冠状病毒病(COVID-19)中的血管性血友病因子前肽:急性和持续的内皮细胞激活的证据。
Br J Haematol. 2021 Feb;192(4):714-719. doi: 10.1111/bjh.17273. Epub 2020 Dec 16.
8
The ADAMTS13-von Willebrand factor axis in COVID-19 patients.新冠病毒感染患者中的ADAMTS13-血管性血友病因子轴
J Thromb Haemost. 2021 Feb;19(2):513-521. doi: 10.1111/jth.15191. Epub 2020 Dec 18.
9
Acute kidney injury and renal replacement therapy in COVID-19 patients: A systematic review and meta-analysis.新型冠状病毒肺炎患者的急性肾损伤与肾脏替代治疗:系统评价和荟萃分析。
Int Immunopharmacol. 2021 Jan;90:107159. doi: 10.1016/j.intimp.2020.107159. Epub 2020 Nov 3.
10
Immunoinflammatory, Thrombohaemostatic, and Cardiovascular Mechanisms in COVID-19.新型冠状病毒肺炎的免疫炎症、血栓形成和心血管机制。
Thromb Haemost. 2020 Dec;120(12):1629-1641. doi: 10.1055/s-0040-1718735. Epub 2020 Oct 29.